{"id":59173,"date":"2025-09-12T09:05:08","date_gmt":"2025-09-12T09:05:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/59173\/"},"modified":"2025-09-12T09:05:08","modified_gmt":"2025-09-12T09:05:08","slug":"deepmind-ceo-demis-hassabis-ai-could-cut-drug-discovery-from-years-to-how-it-is-changing-medicine-worldwide","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/59173\/","title":{"rendered":"DeepMind CEO Demis Hassabis: \u2018AI could cut drug discovery from years to\u2026\u2019; how it is changing medicine worldwide |"},"content":{"rendered":"

\"DeepMind Artificial intelligence (AI) is rapidly transforming industries, and the pharmaceutical sector is poised to be one of its most significant beneficiaries. In a recent Bloomberg Television interview, Demis Hassabis, CEO of DeepMind and Nobel laureate, revealed that AI could dramatically reduce drug discovery timelines, potentially cutting years of research down to mere months. DeepMind\u2019s advanced AI models aim to streamline the identification of drug candidates, enhance precision, and reduce the high failure rates that have historically plagued pharmaceutical development. This breakthrough promises faster access to treatments, reduced costs, and a new era of medical research powered by computational intelligence. <\/p>\n

How AI is changing the drug discovery process: DeepMind CEO reveals<\/p>\n

Traditional drug discovery involves painstaking laboratory experiments, lengthy clinical trials, and significant trial-and-error testing, often taking 10\u201315 years from concept to market. According to Hassabis, AI can radically alter this timeline.\u201cIn the next couple of years, I\u2019d like to see that cut down in a matter of months, instead of years,\u201d Demis Hassabis said in an interview with Bloomberg Television. \u201cThat\u2019s what I think is possible. Perhaps even faster.\u201dDeepMind\u2019s subsidiary, Isomorphic Labs, leverages AI to model complex biological systems, analyse molecular structures, and predict interactions between drugs and proteins. In the Bloomberg interview, Hassabis highlighted that AI can process enormous datasets far faster than human researchers, enabling the identification of promising drug candidates within weeks instead of years.This accelerated approach could not only save valuable time but also optimize resource allocation, ensuring that researchers focus on molecules with the highest likelihood of success.<\/p>\n

How AI predictive models are transforming drug discovery and minimising setbacks<\/p>\n

A major challenge in drug discovery is the high failure rate: many compounds that look promising in early tests fail in later stages due to inefficacy or harmful side effects. Hassabis emphasized that AI\u2019s predictive capabilities could reduce these failures significantly.DeepMind\u2019s models simulate protein folding and chemical interactions, allowing scientists to forecast how molecules behave in the body. The AI can also suggest novel molecular structures that traditional methods might overlook, expanding the pool of potential therapeutics. By prioritizing candidates most likely to succeed, AI improves efficiency and reduces costly setbacks in research.<\/p>\n

AI\u2019s role in speeding up drug development and expanding access<\/p>\n

Hassabis discussed the broader implications of AI-driven drug discovery in the Bloomberg interview. Faster development cycles could allow for quicker responses to pandemics, emerging diseases, and critical health crises. Moreover, AI could facilitate the creation of personalized medicine, tailoring treatments to individual genetic profiles, metabolic rates, and disease characteristics.Beyond speed, AI\u2019s efficiency could lower drug development costs, making treatments more accessible globally. This democratization of medicine could have profound social impacts, particularly for developing nations where access to cutting-edge therapies is limited.<\/p>\n

From Alzheimer\u2019s to rare cancers: AI leads the way<\/p>\n

While Hassabis did not provide specific drug names in the interview, he emphasized that AI models are already being applied to several disease areas, including neurodegenerative disorders, rare genetic conditions, and chronic illnesses. Early studies suggest that computational predictions could significantly reduce the experimental burden and provide actionable leads for human trials.For instance, modeling protein-drug interactions can identify compounds that might mitigate protein misfolding in diseases such as Alzheimer\u2019s. Similarly, AI-driven analysis of molecular pathways could accelerate treatments for rare cancers where conventional drug development is often economically unviable.<\/p>\n

AI-driven drug discovery: Challenges<\/p>\n

Despite its promise, AI-driven drug discovery is not without challenges. Hassabis pointed out several critical considerations:<\/p>\n